<DOC>
	<DOCNO>NCT00002750</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness melphalan patient persistent recurrent neoplastic meningitis .</brief_summary>
	<brief_title>Melphalan Patients With Neoplastic Meningitis</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intrathecal melphalan ( L-PAM ) patient neoplastic meningitis . II . Determine CSF serum pharmacokinetics L-PAM administered via Ommaya reservoir patient . OUTLINE : This dose escalation study . Patients receive melphalan ( L-PAM ) intrathecally ( IT ) via lumbar puncture Ommaya reservoir twice week 2 week . Cohorts 3-6 patient receive escalate dos melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 4 6 patient experience dose-limiting toxicity . At least 3 patient receive L-PAM via Ommaya reservoir MTD . Patients objective significant clinical response may receive additional L-PAM IT week 2 consecutive week , every week 2 dos , monthly thereafter . Patients follow every 12 week 1 year disease progression . PROJECTED ACCRUAL : A minimum 3 child 3 adult per dose level accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy metastatic CSF leptomeningeal/subarachnoid space , include follow : Leukemia Lymphoma Germ cell tumor Persistent recurrent disease require Cytologic evidence malignancy CSF evidence leptomeningeal tumor CT MRI No obstructive hydrocephalus complete block spinal CSF pathway pre study MRI CT No rapidly progress deteriorate neurological deficit PATIENT CHARACTERISTICS : Age : 3 Performance status : Karnofsky 60100 % ( age 10 ) OR Lansky 60100 % ( age 10 ) Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm3* Platelet count great 100,000/mm3* * Lower value allow approval investigator Hepatic : Bilirubin le 3.0 mg/dL Renal : Creatinine le 2 mg/dL Blood urea nitrogen le 30 mg/dL Electrolytes ( include calcium , magnesium , phosphate ) normal Other : No active infection Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior systemic chemotherapy within 3 week entry allow investigator 's discretion At least 3 week since prior intrathecal chemotherapy No concurrent intrathecal chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy CNS No concurrent radiotherapy CNS Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent adult non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>